Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Nov 9;14:1205834. doi: 10.3389/fimmu.2023.1205834

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Cai, Shen, Yang, Shao, Gu, Mou and Che

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

RNA sequencing revealed differentially expressed genes and pathways in diabetic kidney disease and dapagliflozin treatment. (A) Heatmap indicating distinct gene expression patterns of normal (Con1-5) versus diabetic (Db1-6) mouse kidneys. (B) KEGG classification analysis suggested that DEGs between normal and diabetic mouse kidneys were enriched in the immune system (red). (C) KEGG enrichment analysis indicating the top 30 pathways enriched in DEGs between normal and diabetic mouse kidneys. (D) GO enrichment analysis indicating the top 30 pathways enriched in DEGs between normal and diabetic mouse kidneys, highlighting interferon-related pathways (red). (E) Heatmap indicating distinct gene expression patterns of diabetic (Db1-6) versus dapagliflozin-treated diabetic (Db7-12) mouse kidneys. (F) KEGG classification analysis suggesting DEGs between diabetic and dapagliflozin-treated diabetic mouse kidneys were enriched in the immune system (red). (G) KEGG enrichment analysis indicating the top 30 pathways enriched in DEGs between diabetic and dapagliflozin-treated diabetic mouse kidneys. (H) GO enrichment analysis indicating the top 30 pathways enriched in DEGs between diabetic and dapagliflozin-treated diabetic mouse kidneys, highlighting interferon-related pathways (red).